ERBB2 and breast carcinoma: Research involving HER2 targeting agents has progressed overthe years with discoveries showing this to be one of the mostproductive research interests in oncogenic drug development.Trastuzumab targeted therapy as well as agents such aspertuzumab, lapatinib and ado-trastuzumab emtansine (T-DM1)is the standard treatment for HER2+ breast cancer patients.Although there have been several insights into improved HER2targeting and considerable efficacy shown by target agents, somepatients have shown no response to treatment with otherseventually progressing 12.